Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has scheduled its fourth quarter and full year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT.
Investors can access the conference call through toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers. A webcast will be available through the investor relations section of Corvus' website, with replay access for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS), un'azienda biofarmaceutica in fase clinica, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 25 marzo 2025. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET / 13:30 PT.
Gli investitori possono accedere alla conferenza telefonica tramite numeri nazionali senza costi (1-800-717-1738) o internazionali (1-646-307-1865). Un webcast sarà disponibile nella sezione relazioni con gli investitori del sito web di Corvus, con accesso alla registrazione per 90 giorni dopo l'evento.
Corvus Pharmaceuticals (NASDAQ: CRVS), una empresa biofarmacéutica en etapa clínica, ha programado el anuncio de resultados financieros del cuarto trimestre y del año completo 2024 para el 25 de marzo de 2025. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 pm ET / 1:30 pm PT.
Los inversores pueden acceder a la conferencia telefónica a través de números nacionales gratuitos (1-800-717-1738) o internacionales (1-646-307-1865). Un webcast estará disponible en la sección de relaciones con inversores del sitio web de Corvus, con acceso a la grabación durante 90 días después del evento.
Corvus Pharmaceuticals (NASDAQ: CRVS), 임상 단계의 생명공학 회사는 2025년 3월 25일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 오후 4시 30분 ET / 오후 1시 30분 PT에 컨퍼런스 콜과 웹캐스트를 진행할 것입니다.
투자자들은 국내 무료 전화번호(1-800-717-1738) 또는 국제 전화번호(1-646-307-1865)를 통해 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트는 Corvus 웹사이트의 투자자 관계 섹션을 통해 제공되며, 이벤트 후 90일 동안 재생할 수 있습니다.
Corvus Pharmaceuticals (NASDAQ: CRVS), une entreprise biopharmaceutique en phase clinique, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour le 25 mars 2025. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 ET / 13h30 PT.
Les investisseurs peuvent accéder à la conférence téléphonique via des numéros gratuits nationaux (1-800-717-1738) ou internationaux (1-646-307-1865). Un webcast sera disponible dans la section relations investisseurs du site web de Corvus, avec un accès à l'enregistrement pendant 90 jours après l'événement.
Corvus Pharmaceuticals (NASDAQ: CRVS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 25. März 2025 angesetzt. Das Unternehmen wird um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können über die gebührenfreien nationalen (1-800-717-1738) oder internationalen (1-646-307-1865) Nummern auf die Telefonkonferenz zugreifen. Ein Webcast wird im Bereich Investor Relations der Corvus-Website verfügbar sein, mit Zugang zur Aufzeichnung für 90 Tage nach der Veranstaltung.
- None.
- None.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) release Q4 and full year 2024 earnings?
How can investors access the CRVS Q4 2024 earnings call?
How long will the CRVS Q4 2024 earnings webcast replay be available?
What time is the Corvus Pharmaceuticals (CRVS) Q4 2024 earnings call in PT?
